Browse the evidence

Both combined exercise/weight loss and exercise alone reduce low-grade inflammation (CRP) in CAD patients, but only the combined intervention significantly reduces TNFα and suPAR.

While exercise alone reduces general inflammation (CRP), adding weight loss to the regimen further reduces specific inflammatory markers (TNFα, suPAR) associated with plaque instability.

Individual variability in hypertrophic response to resistance exercise is largely determined by endogenous variables such as basal satellite cell content, androgen receptor content, and gene expression profiles, rather than just exogenous training variables.

Accept that your genetic makeup (basal satellite cell count, androgen receptors) influences how much muscle you can build. While you cannot change your genetics, you can maximize your potential by optimizing the primary drivers: consistent resistance training and adequate protein intake. Do not blame your program for genetic ceilings.

Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.

If you have prediabetes and are over 60, have a BMI over 35, or had gestational diabetes, ask your doctor about Metformin. It is a proven, low-cost way to significantly lower your risk of developing full-blown diabetes, with benefits lasting for decades.

Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.

Pioglitazone can prevent diabetes, but it often causes weight gain and other side effects. It is usually not the first choice; Metformin or GLP-1 medications are typically preferred unless Pioglitazone is specifically indicated for your case.

GLP-1/glucagon co-agonists achieve superior weight loss and metabolic improvements compared to GLP-1 mono-agonists by combining central appetite suppression with glucagon-mediated increases in energy expenditure and hepatic lipid oxidation.

GLP-1/glucagon co-agonists (like cotadutide and efinopegdutide) are emerging treatments that target both appetite and energy expenditure. They appear to offer greater weight loss than current GLP-1-only drugs (like semaglutide or liraglutide) and may also improve liver health. However, they carry a higher risk of gastrointestinal side effects like nausea and vomiting. Patients should expect a careful dose-titration process to manage these effects.

Skeletal muscle-derived VEGF, induced by endurance exercise via PGC-1α, mediates training-induced capillarization, enhancing oxygen and substrate delivery to muscle tissue.

Endurance training triggers your muscles to release VEGF locally, which builds new capillaries to improve oxygen delivery. You don't need to monitor blood VEGF levels to know this is happening; it is a standard, autonomous response to the stress of endurance exercise. Consistent training volume is the key driver.

Tirzepatide improves liver fat content and shows potential efficacy in treating nonalcoholic steatohepatitis (NASH) in patients with type 2 diabetes.

For patients with type 2 diabetes and fatty liver, tirzepatide significantly reduces liver fat content more than insulin therapy, potentially helping manage NASH.

Semaglutide significantly reduces high-sensitivity C-reactive protein (hsCRP) levels in patients with type 2 diabetes compared to placebo and active comparators, indicating an anti-inflammatory effect.

If you have type 2 diabetes, semaglutide (whether injected weekly or taken as a daily pill) significantly lowers hsCRP, a key marker of inflammation linked to heart disease risk. This reduction is greater than with placebo or other common diabetes drugs like exenatide or empagliflozin. While part of this benefit comes from losing weight and lowering blood sugar, there appears to be a direct anti-inflammatory effect. For patients with chronic kidney disease, the trend is positive but not statistically significant compared to placebo in this specific analysis, so discuss risks/benefits with your doctor.

In patients with new-onset type 2 diabetes, a weight gain of 10% or more within the first two years is associated with an increased risk of stroke.

If you have recently been diagnosed with type 2 diabetes, try to avoid gaining more than 10% of your body weight in the first two years. Significant weight gain is linked to a higher risk of stroke. Maintaining a stable weight is associated with the lowest risk of cardiovascular events and mortality.

GIP has pleiotropic effects beyond glucose metabolism, including potential benefits for obesity, bone health, and neurodegenerative disorders, making it a candidate for pharmacotherapies.

GIP is not just a blood sugar hormone. It also influences fat storage, bone density, and brain health. This is why new drugs that mimic or modify GIP are being studied for obesity and even neurodegenerative diseases.

Targeting specific inflammatory pathways (IL-1beta, NLRP3) reduces cardiovascular disease events in patients with obesity and elevated inflammation, independent of lipid-lowering effects.

If you have obesity and high inflammation markers (like CRP), your risk of heart disease is significantly driven by inflammation, not just cholesterol. While lifestyle changes are primary, emerging treatments targeting inflammation (like IL-1beta blockers) can reduce heart events by ~15% in high-risk groups, though they carry infection risks and do not fix blood sugar issues.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces systolic and diastolic blood pressure in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (a once-weekly injection) can help lower your blood pressure, which reduces your overall cardiovascular risk. The blood pressure reduction is dose-dependent, meaning higher doses tend to lower BP more.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, including YKL-40, ICAM-1, leptin, and GDF-15.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, such as YKL-40, ICAM-1, leptin, and GDF-15. This reduction in inflammation may contribute to the overall cardiovascular benefits of the drug.

Higher cardiorespiratory fitness (CRF) causally reduces the risk of type 2 diabetes, independent of adiposity (BMI), with a 1-SD increase in genetically predicted fitness associated with an 11% lower risk.

Improving your cardiorespiratory fitness (VO2max) directly lowers your risk of type 2 diabetes, regardless of your weight. Focus on exercises that challenge your heart and lungs (like cycling or running) to improve your body's ability to use oxygen, as this has independent metabolic benefits beyond just burning calories.

Visceral obesity and metabolic syndrome increase the risk of esophageal adenocarcinoma (EAC) through both GERD-dependent mechanisms (increased acid exposure) and GERD-independent mechanisms (systemic inflammation, adipokine signaling, and microbiome alterations).

Maintain a healthy waist circumference and manage metabolic health markers (blood pressure, blood sugar, lipids) to reduce the risk of esophageal adenocarcinoma. This involves addressing visceral fat through diet and exercise, as it impacts cancer risk through both acid reflux and systemic inflammation.

Baseline levels of fibroblast growth factor 21 (FGF-21) significantly predict the magnitude of weight loss during the first three months of dietary intervention, whereas other inflammatory and cardiovascular biomarkers do not.

Current blood tests for inflammatory or cardiovascular proteins cannot tell you which diet (low-fat or low-carb) will work best for you. The only protein that showed predictive power for weight loss magnitude was FGF-21, but even that has limited utility for individualized advice. Focus on adherence to a sustainable dietary pattern rather than seeking a predictive blood test.

Weight loss interventions lead to significant changes in the plasma levels of 130 inflammatory and cardiovascular proteins, with most decreasing alongside BMI reduction.

Losing weight significantly alters your body's inflammatory and cardiovascular protein profile. This confirms that weight loss has systemic biological benefits beyond just size reduction, improving metabolic health markers.

Semaglutide therapy significantly reduces systemic inflammation, as measured by C-reactive protein (CRP) levels, compared to placebo or other glucose-lowering drugs, regardless of whether the patient has type 2 diabetes or obesity without diabetes.

If you are taking semaglutide for diabetes or weight management, you can expect it to lower your systemic inflammation (measured by CRP). This benefit occurs whether you take the pill or the injection, and whether or not you have diabetes. This anti-inflammatory effect is likely a key reason why semaglutide reduces heart disease risk.

Protein hydrolysates may induce a more potent insulinotropic effect (higher insulin response) than intact proteins, although this does not necessarily translate to greater muscle protein synthesis.

Hydrolysates might spike your insulin more than regular protein, but this doesn't mean you build more muscle. Insulin helps inhibit muscle breakdown, but since MPS is the same, the extra insulin spike is likely unnecessary for most people.

GLP-1 analog treatment (semaglutide and liraglutide) reduces short-term appetite, decreases energy intake, and lowers preference for energy-dense foods (high-fat, sweet, and salty) during the weight loss phase, primarily through mechanisms involving delayed gastric emptying and interaction with brain reward pathways.

GLP-1 medications like semaglutide and liraglutide reduce hunger and change food preferences, particularly reducing cravings for high-fat and sweet foods, during the initial 12-18 months of treatment. This leads to significant weight loss (up to 15%). Side effects like nausea are common but can be managed by starting with lower doses and increasing slowly.

Transdermal estrogen therapy (100 µg/day) combined with 12 weeks of progressive resistance training significantly amplifies skeletal muscle mass gains (quadriceps cross-sectional area and whole-body fat-free mass) in early postmenopausal women compared to resistance training with placebo.

If you are an early postmenopausal woman struggling to build muscle despite consistent resistance training, discuss transdermal estrogen therapy with your doctor. This study suggests that adding 100 µg/day of transdermal estradiol to your routine can nearly double your muscle mass gains compared to training alone. This is not a magic bullet but a hormonal optimization that may be particularly relevant if you are in the first 5 years post-menopause.

GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).

If you have fatty liver disease (MASLD) along with diabetes or obesity, GLP-1 medications can help reduce fat in your liver, lower liver enzymes, and improve liver stiffness, potentially slowing or reversing liver damage.

Among GLP-1RAs, Dulaglutide has the lowest risk of causing intolerable gastrointestinal adverse reactions, while Semaglutide and Liraglutide have the highest risk.

If you are experiencing intolerable gastrointestinal side effects on one GLP-1RA (like Semaglutide or Liraglutide), switching to Dulaglutide may reduce these side effects, as it has the lowest risk of intolerable GI reactions among the studied agents.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss and glycemic control, often superior to other GLP-1 agents.

Tirzepatide is a once-weekly injection that helps with weight loss and blood sugar. It works by targeting two hormones. Higher doses lead to more weight loss. It is an option if other GLP-1 drugs are not enough.